KITE Insider Trading Activity and SEC Form 4 Filings
KITE insider trading summary
No open-market insider purchases or sales of Kite Pharma, Inc. (KITE) have been reported on SEC Form 4 in the past 12 months.
Latest KITE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 25, 2017 | Shawn Tomasello | Chief Commercial Officer | Sell | $755K (4,203 @ $179.66) |
| Sep 25, 2017 | Helen Susan Kim | EVP, Business Development | Sell | $570K (3,171 @ $179.66) |
| Sep 25, 2017 | Timothy L. Moore | EVP, Technical Operations | Sell | $760K (4,228 @ $179.66) |
| Sep 25, 2017 | Jeffrey Wiezorek | SVP Clinical Development | Sell | $949K (5,283 @ $179.66) |
| Sep 25, 2017 | Cynthia M Butitta | Chief Operating Officer | Sell | $760K (4,228 @ $179.66) |
| Sep 25, 2017 | Arie Belldegrun | Chairman, President and CEO | Sell | $4.7M (26,347 @ $179.66) |
| Sep 25, 2017 | Paul L Jenkinson | Chief Financial Officer | Sell | $170K (948 @ $179.66) |
| Sep 25, 2017 | David D Chang | EVP, R&D, Chief Medical Off. | Sell | $1.4M (7,927 @ $179.66) |
| Aug 10, 2017 | Cynthia M Butitta | Chief Operating Officer | Sell | $1.1M (9,200 @ $120.52) |
| Aug 10, 2017 | Cynthia M Butitta | Chief Operating Officer | Sell | $702K (5,800 @ $121.03) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.